https://www.selleckchem.com/JAK.html
Treatment increased from 22% in 2006-2009 for metastatic cancer to 50% in 2013-2015 ( .001). Factors associated with treatment were an unknown stage at diagnosis (OR 0.3, 95% CI 0.2-0.4), age ≥75 years (OR 0.2, 95% CI 0.1 - 0.3), PSA doubling time 3 months (OR 0.4, 95% CI 0.3 - 0.6) and a diagnosis between 2013 and 2015 (OR 3.4, 95% CI 2.0 - 5.8). Despite treatment availability, in this large real-world cohort we found treatment utilization to remain low. Despite treatment availability, in this large real-world cohort we found treatment ut